Evidence map›Paper›PMID 40913675›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Price determinants and pricing policies concerning potentially innovative health technologies: a scoping review.

Nicolas S H Xander, Tom Belleman, Maximilian Salcher-Konrad, Anne Hendrickx, Jeffrey Chen, Anne-Sophie Klein Gebbink, Peter Schneider, Kate Morgan, Oliver Groene, Isabelle Durand-Zaleski and 2 more

Abstract readScoping Review
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicolas S H XanderErasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. xander@eshpm.eur.nl.ORCID http://orcid.org/0000-0001-8252-6177
Tom BellemanErasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-9086-6558
Maximilian Salcher-KonradWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Pharmacoeconomics, Austrian National Public Health Institute, Vienna, Austria.ORCID http://orcid.org/0000-0002-5628-5266
Anne HendrickxInternational Association of Mutual Benefit Societies, Brussels, Belgium.ORCID http://orcid.org/0000-0001-5433-3650
Jeffrey ChenErasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Anne-Sophie Klein GebbinkErasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Peter SchneiderWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Department of Pharmacoeconomics, Austrian National Public Health Institute, Vienna, Austria.ORCID http://orcid.org/0000-0003-2113-0368
Kate MorganMyeloma Patients Europe AISBL, Brussels, Belgium.
Oliver GroeneOptiMedis AG, Hamburg, Germany.ORCID http://orcid.org/0000-0002-1099-2950
Isabelle Durand-ZaleskiUnité de Recherche Clinique en Économie de La Santé d'Île-de-France, DRCI, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID http://orcid.org/0000-0002-4078-1476
Frederick W ThielenErasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-0312-5891
Carin A Uyl-de GrootErasmus School of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5808-302X

Funding

HORIZON EUROPE Health 101094938
6 · The paper itself

Abstract

backgroundPolicymakers face challenges in developing pricing policies for potentially innovative healthcare technologies (pIHTs) that balance limited budgets, access, and incentives for innovation. This study aimed to map existing evidence and identify knowledge gaps regarding price determinants and pricing policies for pIHTs and their effect on access and sustainability.

methodsWe conducted a scoping Review of scientific and grey literature in English published between 2014 and September 2023 with pre-specified inclusion and exclusion criteria to identify stakeholder-informed price determinants, pricing policies applied by European Economic Area (EEA) or Organisation for Economic Cooperation and Development (OECD) member states, and their access-related impacts. Literature databases and various stakeholder organisation websites were searched. Further records were included through snowballing and manual addition.

results135 Records were included. Stakeholder views on price determinants were available from 15 records and predominantly involved value-based determinants. Pricing policies in EEA/OECD member states are heterogeneous and often feature a mix of policy interventions and implementation methods. External price referencing (EPR), while yielding short-term affordability improvements, is associated with price inequities and launch strategies impairing patient access. Policies combining pricing methods and considering a pIHT's value have more positive access-related impact but may face feasibility and implementation challenges. Two records mentioned medical device pricing; none featured environmental aspects.

conclusionWhile EPR is commonly applied across Europe, value-informed pricing in connection with health technology assessment is more favoured regarding pIHT access in the literature. Knowledge gaps concern medical device pricing, stakeholder views on price determinants, and the implementation of environmental aspects in pIHT pricing.

Indexed as

Biomedical TechnologyCosts and Cost AnalysisHealth PolicyEuropeHumansInnovationPatient accessPharmaceutical pricingPrice determinantsPricing policies

Identifiers

PMID40913675
PMCPMC13046678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.